<DOC>
	<DOC>NCT00548340</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.</brief_summary>
	<brief_title>VEC-162 Study in Adult Patients With Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<criteria>Males and females with a diagnosis of primary insomnia as defined in DSMIV. Habitual bedtime between 9:00 pm and 1:00 am. No history or evidence of restless leg syndrome or periodic limb movement disorder or sleep apnea. Patients must sign a written consent form. History of drug or alcohol abuse as defined in DSMIV. History of psychiatric disorders, including Major Depressive Disorder, Generalized Anxiety Disorder and delirium. History of chronic obstructive pulmonary disease (COPD), seizures, sleep apnea, narcolepsy, circadianrhythm sleep disorder, parasomnia or any sleep disorder other than chronic insomnia. Recent history of shift work or jet lag.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>